Quarterly report pursuant to Section 13 or 15(d)

Schedule of Stock Awards Granted (Details)

v3.22.1
Schedule of Stock Awards Granted (Details)
 9 Months Ended
Mar. 31, 2022
USD ($)
$ / shares
shares
Share-Based Payment Arrangement [Abstract]  
Number of Shares, Outstanding, Beginning balance | shares 604,404
Weighted Average Exercise Price, Outstanding, Beginning balance | $ / shares $ 2.18
Weighted Average Remaining Contractual Term (Years), Outstanding, Beginning balance 4 years 8 months 12 days
Aggregate Intrinsic Value, Outstanding, Beginning balance | $ $ 2,802,420
Number of Shares, Granted | shares 879,429
Weighted Average Exercise Price, Granted | $ / shares $ 6.16
Number of Shares, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Number of Shares, Forfeited | shares
Weighted Average Exercise Price, Forfeited | $ / shares
Number of Shares, Outstanding, Ending balance | shares 1,483,833
Weighted Average Exercise Price, Outstanding, Ending balance | $ / shares $ 4.54
Weighted Average Remaining Contractual Term (Years), Outstanding, Ending balance 4 years 6 months
Aggregate Intrinsic Value, Outstanding, Ending balance | $ $ 3,765,907
Number of Shares, Exercisable, Ending balance | shares 225,741
Weighted Average Exercise Price, Exercisable, Ending balance | $ / shares $ 2.54
Weighted Average Remaining Contractual Term (Years), Exercisable, Ending balance 4 years
Aggregate Intrinsic Value, Exercisable, Ending balance | $ $ 1,025,177